Half Year 2026 Integral Diagnostics Ltd Earnings Call Transcript
Key Points
- Integral Diagnostics Ltd (ASX:IDX) reported strong revenue growth of 55.6% to $393.5 million, including contributions from the Capital merger.
- The company achieved an improved operating EBITDA margin of 20.6%, up 230 basis points from the previous year.
- Operating diluted earnings per share increased by 66.2%, and the interim dividend per share rose by 32%.
- Annual synergies from the Capital merger exceeded expectations, achieving more than $14 million, surpassing the initial estimate of $10 million.
- The company is well-positioned to benefit from government initiatives such as MRI deregulation and the National CT lung cancer screening program, which are expected to drive further revenue growth and margin expansion.
- The New Zealand market faced pricing pressures, particularly due to reductions in private health insurance reimbursement, impacting revenue growth.
- The Capital business experienced lower growth compared to the legacy IDX business, partly due to a reliance on GP referrals, which have been slow to recover.
- There are ongoing challenges with clinical labor shortages, especially in regional Australia, affecting operational efficiency.
- The integration of clinical and non-clinical systems across the group is ongoing, with associated costs and complexities.
- Non-recurring items, including transaction and integration costs from the Capital merger, significantly impacted profitability, with expectations of continued costs in the near term.
Thank you for standing by and welcome to the Integral Diagnostics first half fiscal year '26 results call. (Operator Instructions)
I would now like to hand the conference over to Doctor Ian Kadish, CEO. Please go ahead.
Thank you very much, Alicia, and good morning all.
My name is Ian Kadish.
I am the chief executive and managing director of Integral Diagnostics.
I'm joined this morning by Craig White, who is our Chief Financial Officer.
We're pleased this morning to be able to deliver another strong set of results for Integral Diagnostics for the first half of financial year '26.
With solid revenue growth.
And improve margins on all earnings lines.
We saw strong revenue growth of 55.6% to 393.
$5 million which included the six-month contribution from Capital.
We've also delivered an improved operating EBITDA margin of 20.6%. Which is up 230 basis points versus
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
